Enveric Biosciences Inc

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. It has created a portfolio of new chemical entities for specific mental health indications using The Psybrary, a discovery and development platform. The company's lead program is the EVM201 series that comprise next generation synthetic psilocybin analogues that are considered prodrugs of the active metabolite psilocin. It is also advancing its third generation of therapeutics, the EVM301 Series, for treating central nervous system disorders. The company is headquartered in Naples, Florida with offices in Cambridge, Massachusetts and Calgary, Canada.